Latest: FDA Approves New Biosimilar for Oncology Treatment

STAT+: Viking Therapeutics oral weight loss drug hits mark in mid-stage trial but disappoints investors

0 Mins
A new oral weight loss drug developed by Viking Therapeutics hit the mark in a mid-stage clinical trial, but the side effect and discontinuation rates disappointed investors.
Tags:
📢

Advertisement

300x250 Banner

Recent Content

COPD Biologics: Early Treatment Insights

Pulmonology • 2 hours ago

Antihypertensive Medication Guidelines

Cardiology • 4 hours ago

Juvenile Arthritis Care Transition

Rheumatology • 6 hours ago